HALO241220C50000
- 0.10
- +0.05+100.00%
Halozyme Therapeutics Newsroom
Those Who Invested in Halozyme Therapeutics (NASDAQ:HALO) Five Years Ago Are up 159%
Express News | HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $68 Price Target
Johnson & Johnson Says Injectable Rybrevant Rejected by FDA
How Much Upside Is Left in Halozyme Therapeutics (HALO)? Wall Street Analysts Think 27.08%
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This Is How Much It'd Be Worth Now
(HALO) - Analyzing Halozyme Therapeutics's Short Interest
Editas Stock Rises on Updated Data From SCD Study of Reni-Cel
KOD Stock Up as Jefferies Upgrades Rating on Huge Pipeline Potential
Here Is Why Growth Investors Should Buy Halozyme Therapeutics (HALO) Now
Short Stock Ideas From Each Sector With Earnings Quality in the Bottom 20%
Halozyme to Present at Upcoming Investor Conferences
HALO Withdraws Acquisition Bid for EVO, Reaffirms '24 View, Stock Up
Halozyme Therapeutics Price Target Maintained With a $68.00/Share by HC Wainwright & Co.
Evotec Refutes Halozyme Therapeutics' Reason for Buyout Bid Withdrawal
Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet
Trending: Halozyme Drops Bid for Evotec
Halozyme Therapeutics (HALO) Upgraded to Buy: Here's Why
Express News | Evotec Confirms Review Of Halozyme's Withdrawn EUR 11.00/Share Proposal, Reiterates Confidence In Standalone Growth Strategy
Express News | U.S.-Listed Shares of Evotec Down 19.8% Premarket
Sector Update: Health Care Stocks Advance Premarket Friday